Litfulo is a medicine used to treat adults and adolescents over 12 years of age with severe alopecia areata, an autoimmune disease (a disease caused by the body’s own defence system attacking normal tissue) causing hair loss of the scalp or other parts of the body. Litfulo contains the active substance ritlecitinib.
Therapeutic Indication
### Therapeutic indication Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
Therapeutic Area (MeSH)
N/AATC Code
L04AF08
ATC Item
ritlecitinib
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| ritlecitinib tosilate | N/A | Ritlecitinib Tosilate |
EMA Name
Litfulo
Medicine Name
Litfulo
Aliases
N/ANo risk management plan link.
